Thrivent Financial for Lutherans’s PDL BioPharma, Inc. PDLI Stock Holding History

Thrivent Financial for Lutherans’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-300,000	Closed	-$974K	–	2332
2019 Q4	$974K	Buy	+300,000	New	+$871K	﹤0.01%	1508
2019 Q3	–	Sell	-118,046	Closed	-$371K	–	2277
2019 Q2	$371K	Buy	+118,046	New	+$383K	﹤0.01%	1959
2017 Q2	–	Sell	-969,050	Closed	-$2.2M	–	2138
2017 Q1	$2.2M	Buy	+969,050	New	+$2.14M	0.01%	812
2016 Q4	–	Sell	-240,320	Closed	-$805K	–	2066
2016 Q3	$805K	Buy	+240,320	New	+$763K	﹤0.01%	1227
2014 Q2	–	Sell	-314,303	Closed	-$2.61M	–	1775
2014 Q1	$2.61M	Sell	314,303 -353,925	-53%	-$3.03M	0.02%	537
2013 Q4	$5.64M	Sell	668,228 -374,200	-36%	-$3.15M	0.03%	412
2013 Q3	$8.31M	Buy	1,042,428 +208,328	+25%	+$1.67M	0.05%	341
2013 Q2	$6.44M	Buy	+834,100	New	+$6.5M	0.04%	387

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Thrivent Financial for Lutherans's PDLI Position: Q1 2020 in Review

Thrivent Financial for Lutherans sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 300,000 shares — an estimated $974K sold.

Thrivent Financial for Lutherans first reported a position in PDLI in Q2 2013 and held it in 8 quarters. The position peaked at $8.31M in Q3 2013. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Thrivent Financial for Lutherans reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
Thrivent Financial for Lutherans sold 300,000 PDL BioPharma, Inc. shares in Q1 2020, an estimated $974K.
Thrivent Financial for Lutherans first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 8 quarters.
Thrivent Financial for Lutherans's PDL BioPharma, Inc. position peaked at $8.31M in Q3 2013.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2020, filed 15 May 2020.